Parenteral Drug Association filed 2 comments on this docket between Feb 19, 2008 and Feb 26, 2008. 0 other organizations filed here. The comment window closed 6734d ago.
Robert B. Myers, Parenteral Drug Association - ...PDA is pleased to offer comments on the FDA's proposed changes to the GMP requirements defined in 21 CFR Sections 210 and 211....
Attached are the Parenteral Drug Association's (PDA) comments on FDA's proposed changes to tje GMP requirements as defined in 21 CFR Sections 210 and 11, Federal Dockets Management System Docket FDA-2007-0614 Robert L. Dana, Vice President, Quality Regulatory Affairs, PDA ... comments on FDA's proposed changes to the GMP requirements as defined in 21 CFR Sections 210 and 11,
Amendment to the Current Good Manufacturing Practice Regulations for Finished Pharmaceuticals; Companion Document to the Direct Final Rule
View on regulations.gov →